Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.
The heliobacter pylori bacterium is the main cause of stomach ulcers, and it also a known risk factor for non-cardia gastric cancer.
Researchers found that the vagal nerve contributes to the growth of gastric tumors through the release of a neurotransmitter.
In a massive effort to catalog the molecular causes of stomach cancer, scientists have identified four subtypes of tumors based on shared mutations and other molecular abnormalities. They say the new classification promises to advance clinical research to develop improved therapies for the third-leading cancer killer worldwide.
Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.
Stomach and bowel cancer—two of the most common cancers worldwide—could be treated with a class of medicines that are currently used to treat a blood disorder, according to new research.
This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.
Survivors of Hodgkin lymphoma who received subdiaphragmatic radiotherapy had dose-dependent increased risk for stomach cancer, researchers discovered.
Stomach cancer, one of the leading causes of cancer death worldwide, actually falls into three broad subtypes that respond differently to currently available therapies, according to new research.
Non-Hodgkin lymphoma rates down but carcinoma rates fairly constant from 1980 to 2007.
Mutations were seen in FAT4 and ARID1A, involved in cell adhesion and chromatin remodeling.
With the exception of lung cancer in women and pancreatic cancer, mortality from major cancers is expected to decline in the European Union in 2012.
A large study showed that people with AIDS are 6.9-fold more likely than the general population to develop stomach malignancies and 2.7 times more likely to have esophageal malignancies.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|